185 related articles for article (PubMed ID: 17530309)
1. Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial.
Janka HU; Högy B
Eur J Health Econ; 2008 May; 9(2):165-70. PubMed ID: 17530309
[TBL] [Abstract][Full Text] [Related]
2. [BOT with insulin glargine versus BOT with insulin detemir: comparison of treatment costs in type 2 diabetes based on the results of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study from the German Statutory Health Insurance perspective].
Schädlich PK; Koltermann KC; Dippel FW; Hagenmeyer EG; Häussler B
MMW Fortschr Med; 2010 Oct; 152 Suppl 3():89-95. PubMed ID: 21595152
[No Abstract] [Full Text] [Related]
3. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
4. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
[TBL] [Abstract][Full Text] [Related]
5. A comparison of costs for four oral antidiabetic regimens within a managed care population.
Stockl K; Vanderplas AM; Nicklasson L
Manag Care Interface; 2003 Jul; 16(7):31-6. PubMed ID: 12908215
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting.
Mittendorf T; Smith-Palmer J; Timlin L; Happich M; Goodall G
Diabetes Obes Metab; 2009 Nov; 11(11):1068-79. PubMed ID: 19732121
[TBL] [Abstract][Full Text] [Related]
7. [Costs of the treatment of hyperglycemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: results of the German CoDiM study].
von Ferber L; Köster I; Hauner H
Med Klin (Munich); 2006 May; 101(5):384-93. PubMed ID: 16685485
[TBL] [Abstract][Full Text] [Related]
8. A short-term cost-of-treatment model for type 2 diabetes: comparison of glipizide gastrointestinal therapeutic system, metformin, and acarbose.
Ramsdell JW; Grossman JA; Stephens JM; Botteman MF; Arocho R
Am J Manag Care; 1999 Aug; 5(8):1007-24. PubMed ID: 10558125
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
Tunis SL; Sauriol L; Minshall ME
Appl Health Econ Health Policy; 2010; 8(4):267-80. PubMed ID: 20578781
[TBL] [Abstract][Full Text] [Related]
10. Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany.
Pscherer S; Dietrich ES; Dippel FW; Neilson AR
Int J Clin Pharmacol Ther; 2010 Feb; 48(2):129-37. PubMed ID: 20137765
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
Gao L; Zhao FL; Li SC
Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
[TBL] [Abstract][Full Text] [Related]
12. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
[TBL] [Abstract][Full Text] [Related]
13. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.
Aquilante CL; Zhang W; McCollum M
Curr Med Res Opin; 2007 Mar; 23(3):489-94. PubMed ID: 17355730
[TBL] [Abstract][Full Text] [Related]
14. [Current cost analysis in the management of diabetes mellitus].
Oberender P
Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S110-4; discussion S124-6. PubMed ID: 18686219
[TBL] [Abstract][Full Text] [Related]
15. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.
Hansen RA; Farley JF; Droege M; Maciejewski ML
Clin Ther; 2010 Jul; 32(7):1308-19. PubMed ID: 20678679
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics.
Levin P
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():66-75. PubMed ID: 18577158
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
Ericsson Å; Pollock RF; Hunt B; Valentine WJ
J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
[TBL] [Abstract][Full Text] [Related]
19. Direct costs and health-related resource utilisation in the 6 months after insulin initiation in German patients with type 2 diabetes mellitus in 2006: INSTIGATE study.
Liebl A; Breitscheidel L; Nicolay C; Happich M
Curr Med Res Opin; 2008 Aug; 24(8):2349-58. PubMed ID: 18606055
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and costs of diabetes treated with insulin in France.
Detournay B; Raccah D; Cadilhac M; Eschwège E
Diabetes Metab; 2005 Jun; 31(3 Pt 2):3-18. PubMed ID: 16142041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
